Natl Toxicol Program Tech Rep Ser. 1996 Jul;454:1-380.
Nickel sulfate hexahydrate is used in nickel plating, as a mordant in dyeing and printing textiles, as a blackening agent for zinc and brass, and in the manufacture of organic nickel salts. Nickel sulfate hexahydrate was nominated by the National Cancer Institute to the NTP as part of a class study of nickel compounds for which there was little information on the toxic and carcinogenic effects of inhalation exposure. Male and female F344/N rats and B6C3F1 mice were exposed to nickel sulfate hexahydrate (greater than 98% pure) by inhalation for 16 days, 13 weeks, or 2 years. Genetic toxicology studies were conducted in L5178Y mouse lymphoma cells. 16-DAY STUDY IN RATS: Groups of five male and five female F344/N rats were exposed to 0, 3.5, 7, 15, 30, or 60 mg nickel sulfate hexahydrate/m(3) (equivalent to 0, 0.7, 1.4, 3.1, 6.1, or 12.2 mg nickel/m(3)). Rats were exposed on weekdays only, for a total of 12 exposure days during a 16-day period. Additional groups of four or five male and female F344/N rats were exposed to 0, 3.5, 15, or 30 mg nickel sulfate hexahydrate/m(3)for tissue burden studies. In the core study, two 60 mg/m(3) males, one 30 mg/m(3) female, and all 60 mg/m(3)females died before the end of the study. Final mean body weights of all exposed groups of males and females were significantly lower than those of the controls, as were mean body weight gains of male rats. Clinical findings included increased rates of respiration and reduced activity levels in rats in all exposure groups, except those exposed to 3.5 mg/m(3). Absolute lung weights of 60 mg/m(3) males and of all exposed groups of females were significantly greater than those of the controls, as were the relative lung weights of all exposed groups of males and females. Inflammation (including degeneration and necrosis of the bronchiolar epithelium) occurred in the lungs of all exposed groups of males and females. Atrophy of the olfactory epithelium occurred in the nasal passages of all exposed groups of males (except 60 mg/m(3)) and in 15, 30, and 60 mg/m(3) females. Lymphoid hyperplasia in the bronchial or mediastinal lymph nodes was observed in 30 mg/m(3) males and in 60 mg/m(3) males and females. The concentration of nickel in the lungs of all exposed groups of males and females was greater than in control animals. 16-DAY STUDY IN MICE: Groups of five male and five female B6C3F1 mice were exposed to 0, 3.5, 7, 15, 30, or 60 mg nickel sulfate hexahydrate/m(3). Mice were exposed on weekdays only, for a total of 12 exposure days during a 16-day period. Additional groups of five male and five female B6C3F1 mice were exposed to 0 or 3.5 mg nickel sulfate hexahydrate/m(3)for tissue burden studies. All core study mice exposed to 7 mg/m(3) or greater died before the end of the study; all control and 3.5 mg/m(3)mice survived to the end of the study. Final mean body weights and weight gains of 7, 15, 30, and 60 mg/m(3)males and females were significantly less than those of the controls, and clinical findings in these groups included emaciation, lethargy, and rapid respiration rates. Absolute and relative lung weights of male and female mice exposed to 7 mg/m(3) or greater were significantly greater than those of the controls. Only tissues from mice exposed to 0, 3.5, or 7 mg/m(3) were examined histopathologically. Inflammation occurred in the lungs of 3.5 and 7 mg/m(3) males and females; necrosis of the alveolar and bronchiolar epithelium was a component of the inflammation in 7 mg/m(3)males and females. In addition, atrophy of the olfactory epithelium of the nasal passages was observed in 3.5 mg/m(3) males and females. Nickel concentrations in the lungs of mice exposed to 3.5 mg/m(3) were greater than those in the controls. 13-WEEK STUDY IN RATS: Groups of ten male and ten female F344/N rats were exposed to 0, 0.12, 0.25, 0.5, 1, or 2 mg nickel sulfate hexahydrate (equivalent to 0, 0.03, 0.06, 0.11, 0.22, or 0.44 mg nickel/m(3)), 5 days per week for 13 weeks. Additional groups of six male and six female F344/N rats were exposed to 0, 0.12, 0.5, or 2 mg nic mg nickel sulfate hexahydrate/m(3)for tissue burden studies. In the core study, one 2 mg/m(3)male rat died before the end of the study; all other males and all females survived until the end of the study. Final mean body weights and body weight gains of all exposed groups were similar to those of the controls. There were no significant clinical findings noted during the study. Exposure-related increases in neutrophil and lymphocyte numbers occurred and were most pronounced in female rats. With the exception of 0.12 mg/m(3)rats, absolute and relative lung weights of all exposed groups were generally significantly greater than those of the controls. Exposure-related increases in the incidence and severity of inflammatory lesions (alveolar macrophages, chronic inflammation, and interstitial infiltration) occurred in the lungs of all exposed groups of males and females. Lymphoid hyperplasia of the bronchial and/or mediastinal lymph nodes occurred in males exposed to 0.5 mg/m(3)or greater. Atrophy of the olfactory epithelium occurred in males and females exposed to 0.5, 1, and 2 mg/m(3)and in 0.25 mg/m(3)females. The concentration of nickel in the lungs of 0.5 and 2 mg/m(3) rats was greater than that in the lungs of control animals at 4, 9, and 13 weeks for males and at 13 weeks for females. 13-WEEK STUDY IN MICE: Groups of ten male and ten female B6C3F1 mice were exposed to 0, 0.12, 0.25, 0.5, 1, or 2 mg nickel sulfate hexahydrate, 5 days per week for 13 weeks. Additional groups of up to five or six male and female B6C3F1 mice were exposed to 0, 0.12, 0.5, or 2 mg nickel sulfate hexahydrate/m(3)for tissue burden studies. In the core study, four control males, three control females, and one 0.12 mg/m(3)male died before the end of the study; the deaths were not considered to be chemical related, and all other mice survived to the end of the study. The final mean body weights and body weight gains of all exposed groups were similar to those of the controls. There were no chemical-related clinical findings. Hematology changes similar to those reported in female rats occurred in female mice, but the mice were minimally affected. The absolute and relative lung weights of 1 mg/m(3)males and 2 mg/m(3)males and females were significantly greater than those of the controls. Increased numbers of alveolar macrophages occurred in all males and females exposed to 0.5 mg/m(3)or greater. Chronic active inflammation and fibrosis occurred in 1 and 2 mg/m(3)males and females. Lymphoid hyperplasia of the bronchial lymph node and atrophy of the olfactory epithelium in the nasal passages were observed in 2 mg/m(3)males and females. Nickel concentration in the lung of 2 mg/m(3)females was significantly greater than in control animals. 2-YEAR STUDY IN RATS: Groups of 63 to 65 male and 63 to 64 female rats were exposed to nickel sulfate hexahydrate by inhalation at concentrations of 0, 0.12, 0.25, or 0.5 mg/m(3) (equivalent to 0, 0.03, 0.06, or 0.11 mg nickel/m(3)). Animals were exposed for 6 hours plus T90 (8 minutes) 5 days per week for 104 weeks. Five male and five female rats from each group were evaluated at 7 months for histopathology; an additional seven males and seven females from each group were evaluated at 7 months for nickel tissue burden in the lung and kidney; and five males and five females from each group were evaluated at 15 months for alterations in hematology, nickel tissue burden in the lung and kidney, and histopathology. Survival, Body Weights, Clinical Findings, and Hematology The survival rates of all exposed groups of males and females were similar to those of the controls. Mean body weights of 0.5 mg/m(3)female rats were slightly lower (6% to 9%) than those of the controls throughout the second year of the study; final mean body weights of all exposed groups of males and 0.12 and 0.25 mg/m(3)females were similar to those of the controls. There were no clinical findings or hematology differences that were considered to be related to nickel sulfate hexahydrate administration. Pathology Findings No exposure-related neoplasms occurred in male or female rats exposed by inhalation to nickel sulfate hexahydrate for 2 years. Increased incidences of inflammatory lung lesions were generally observed in all exposed groups of male and female rats at the end of the study. The incidences of chronic active inflammation, macrophage hyperplasia, alveolar proteinosis, and fibrosis were markedly increased in male and female rats exposed to 0.25 or 0.5 mg/m(3). Increased incidences of lymphoid hyperplasia in the bronchial lymph nodes occurred in 0.5 mg/m(3)male and female rats at the end of the 2-year study. The incidences of atrophy of the olfactory epithelium in 0.5 mg/m(3)males and females were significantly greater than those in controls at the end of the study. Tissue Burden Analyses Lung nickel burdens in exposed male and female rats were greater than those in the controls at the 7- and 15-month interim evaluations, and lung nickel burdens values increased with increasing exposure concentration. 2-YEAR STUDY IN MICE: Groups of 80 male and 80 female mice were exposed to nickel sulfate hexahydrate by inhalation at concentrations of 0, 0.25, 0.5, or 1 mg/m(3) (equivalent to 0, 0.06, 0.11, or 0.22 mg nickel/m(3)). Animals were exposed for 6 hours plus T90 (8 minutes) 5 days per week for 104 weeks. Five male and five female mice from each group were evaluated at 7 months for histopathology; five males and five females from each group were evaluated at 7 months for nickel tissue burden in the lung and kidney; five males and five females from each group were evaluated at 15 months for alterations in hematology and histopathology; and five males and five females from each group were evaluated at 15 months for nickel tissue burden in the lung and kidney. Survival, Body Weights, Clinical Findings, and Hematology The survival rates of all exposed groups of males and females were similar to those of the controls. The mean body weights of 1 mg/m(3)males and of all exposed groups of females were lower than those of the controls during the second year of the study. There were no clinical findings or hematology differences considered to be related to chemical exposure. Pathology Findings Inflammatory lesions of the lung generally occurred in all exposed groups of male and female mice at the end of the 2-year study. These lesions included macrophage hyperplasia, chronic active inflammation, bronchialization (alveolar epithelial hyperplasia), alveolar proteinosis, and infiltrating cells in the interstitium. Incidences of macrophage hyperplasia and/or lymphoid hyperplasia occurred in the bronchial lymph nodes of most of the 1 mg/m(3)males and females and in some 0.5 mg/m(3)females at the end of the 2-year study. Atrophy of the olfactory epithelium was observed in 0.5 and 1 mg/m(3)males and in all exposed groups of females at the end of the 2-year study. Tissue Burden Analyses At the 7- and 15-month interim evaluations, lung nickel burden parameters measured in control and exposed groups were below the limit of detection. Absolute lung weights of 0.5 and 1 mg/m(3)lung burden study females were significantly greater than those of the controls at 15 months. GENETIC TOXICOLOGY: Nickel sulfate hexahydrate (500 to 800 g/mL) was tested for induction of trifluorothymidine resistance in L5178Y mouse lymphoma cells. A positive response was observed in the absence of S9. The test was not performed with S9. CONCLUSIONS: Under the conditions of these 2-year inhalation studies, there was no evidence of carcinogenic activity of nickel sulfate hexahydrate in male or female F344/N rats exposed to 0.12, 0.25, or 0.5 mg/m(3) (0.03, 0.06, or 0.11 mg nickel/m(3)). There was no evidence of carcinogenic activity of nickel sulfate hexahydrate in male or female B6C3F1 mice exposed to 0.25, 0.5, or 1 mg/ m3 (0.06, 0.11, or 0.22 mg nickel/m(3)). Exposure of rats to nickel sulfate hexahydrate by inhalation for 2 years resulted in increased incidences of chronic active inflammation, macrophage hyperplasia, alveolar proteinosis, and fibrosis of the lung; lymphoid hyperplasia of the bronchial lymph node; and atrophy of the olfactory epithelium. Exposure of mice to nickel sulfate hexahydrate by inhalation for 2 years resulted in increased incidences of chronic active inflammation, bronchialization (alveolar epithelial hyperplasia), macrophage hyperplasia, interstitial infiltration, and alveolar proteinosis of the lung; lymphoid and macrophage hyperplasia of the bronchial lymph node; and atrophy of the olfactory epithelium. Synonyms: Blue salt; hexahydrate, nickel (2+) salt; nickel monosulfate hexahydrate; nickel (2+) sulfate hexahydrate; nickel (II) sulfate hexahydrate; nickel sulphate hexahydrate; nickelous sulfate hexahydrate; nickelous sulphate hexahydrate; single nickel salt, sulfuric acid
六水合硫酸镍用于镀镍、作为纺织品染色和印花的媒染剂、作为锌和黄铜的发黑剂以及用于制造有机镍盐。美国国家癌症研究所将六水合硫酸镍提名为国家毒理学计划(NTP)镍化合物类别研究的一部分,对于吸入暴露的毒性和致癌作用,当时相关信息很少。雄性和雌性F344/N大鼠以及B6C3F1小鼠通过吸入六水合硫酸镍(纯度大于98%)16天、13周或2年。在L5178Y小鼠淋巴瘤细胞中进行了遗传毒理学研究。
大鼠16天研究:将每组五只雄性和五只雌性F344/N大鼠暴露于0、3.5、7、15、30或60毫克六水合硫酸镍/立方米(相当于0、0.7、1.4、3.1、6.1或12.2毫克镍/立方米)。大鼠仅在工作日暴露,在16天期间总共暴露12天。另外几组四只或五只雄性和雌性F344/N大鼠暴露于0、3.5、15或30毫克六水合硫酸镍/立方米用于组织负荷研究。在核心研究中,两只60毫克/立方米的雄性大鼠、一只30毫克/立方米的雌性大鼠以及所有60毫克/立方米的雌性大鼠在研究结束前死亡。所有暴露组的雄性和雌性大鼠的最终平均体重显著低于对照组,雄性大鼠的平均体重增加量也显著低于对照组。临床发现包括所有暴露组大鼠的呼吸频率增加和活动水平降低,但暴露于3.5毫克/立方米的组除外。60毫克/立方米雄性大鼠以及所有暴露组雌性大鼠的绝对肺重量显著大于对照组,所有暴露组雄性和雌性大鼠的相对肺重量也显著大于对照组。所有暴露组雄性和雌性大鼠的肺部均出现炎症(包括细支气管上皮的变性和坏死)。所有暴露组雄性大鼠(60毫克/立方米组除外)以及15、30和60毫克/立方米雌性大鼠的鼻腔嗅上皮出现萎缩。在30毫克/立方米雄性大鼠以及60毫克/立方米雄性和雌性大鼠中观察到支气管或纵隔淋巴结中的淋巴样增生。所有暴露组雄性和雌性大鼠肺部的镍浓度均高于对照动物。
小鼠16天研究:将每组五只雄性和五只雌性B6C3F1小鼠暴露于0、3.5、7、15、30或60毫克六水合硫酸镍/立方米。小鼠仅在工作日暴露,在16天期间总共暴露12天。另外几组五只雄性和五只雌性B6C3F1小鼠暴露于0或3.5毫克六水合硫酸镍/立方米用于组织负荷研究。所有暴露于7毫克/立方米或更高浓度的核心研究小鼠在研究结束前死亡;所有对照组和3.5毫克/立方米组的小鼠存活至研究结束。7、15、3天研究:将每组十只雄性和十只雌性F344/N大鼠暴露于0、0.12、0.25、0.5、1或2毫克六水合硫酸镍(相当于0、0.03、0.06、0.11、0.22或0.44毫克镍/立方米),每周5天,共13周。另外几组六只雄性和六只雌性F344/N大鼠暴露于0、0.12、0.5或2毫克六水合硫酸镍/立方米用于组织负荷研究。在核心研究中,一只2毫克/立方米的雄性大鼠在研究结束前死亡;所有其他雄性和所有雌性大鼠存活至研究结束。所有暴露组的最终平均体重和体重增加量与对照组相似。研究期间未发现明显的临床发现。与暴露相关的中性粒细胞和淋巴细胞数量增加,在雌性大鼠中最为明显。除0.12毫克/立方米组大鼠外,所有暴露组的绝对和相对肺重量通常显著大于对照组。所有暴露组雄性和雌性大鼠的肺部炎症病变(肺泡巨噬细胞、慢性炎症和间质浸润)的发生率和严重程度均有所增加。暴露于0.5毫克/立方米或更高浓度的雄性大鼠出现支气管和/或纵隔淋巴结的淋巴样增生。暴露于0.5、1和2毫克/立方米的雄性和雌性大鼠以及0.25毫克/立方米的雌性大鼠出现嗅上皮萎缩。在第4、9和13周时,0.5和2毫克/立方米雄性大鼠肺部的镍浓度高于对照组雄性大鼠,在第13周时,0.5和2毫克/立方米雌性大鼠肺部的镍浓度高于对照组雌性大鼠。
小鼠13周研究:将每组十只雄性和十只雌性B6C3F1小鼠暴露于0、0.12、0.25、0.5、1或2毫克六水合硫酸镍,每周5天,共13周。另外几组最多五只或六只雄性和雌性B6C3F1小鼠暴露于0、0.12、0.5或2毫克六水合硫酸镍/立方米用于组织负荷研究。在核心研究中,四只对照雄性、三只对照雌性和一只0.12毫克/立方米的雄性大鼠在研究结束前死亡;这些死亡被认为与化学物质无关,所有其他小鼠存活至研究结束。所有暴露组的最终平均体重和体重增加量与对照组相似。未发现与化学物质相关的临床发现。雌性小鼠出现了与雌性大鼠报告的类似血液学变化,但影响极小。1毫克/立方米雄性和2毫克/立方米雄性和雌性的绝对和相对肺重量显著大于对照组。暴露于0.5毫克/立方米或更高浓度的所有雄性和雌性小鼠的肺泡巨噬细胞数量增加。1和2毫克/立方米雄性和雌性出现慢性活动性炎症和纤维化。在2毫克/立方米雄性和雌性中观察到支气管淋巴结的淋巴样增生和鼻腔嗅上皮萎缩。2毫克/立方米雌性小鼠肺部的镍浓度显著高于对照动物。
大鼠2年研究:将63至65只雄性和63至64只雌性大鼠通过吸入暴露于浓度为0、0.12、0.25或0.5毫克/立方米(相当于0、0.03、0.06或0.11毫克镍/立方米)的六水合硫酸镍。动物每周5天,每天暴露6小时加T90(8分钟),共104周。每组五只雄性和五只雌性大鼠在7个月时进行组织病理学评估;每组另外七只雄性和七只雌性大鼠在7个月时评估肺部和肾脏中的镍组织负荷;每组五只雄性和五只雌性大鼠在第组五只雄性和五只雌性小鼠在15个月时进行血液学改变、肺部和肾脏中的镍组织负荷以及组织病理学评估。
生存、体重、临床发现和血液学:所有暴露组雄性和雌性的生存率与对照组相似。在研究的第二年,0.5毫克/立方米雌性大鼠的平均体重略低于对照组(6%至9%);所有暴露组雄性以及0.12和0.25毫克/立方米雌性大鼠的最终平均体重与对照组相似。未发现被认为与六水合硫酸镍给药相关的临床发现或血液学差异。
通过吸入暴露于六水合硫酸镍2年的雄性或雌性大鼠未出现与暴露相关的肿瘤。在研究结束时,所有暴露组雄性和雌性大鼠肺部炎症病变的发生率普遍增加。暴露于0.25或0.5毫克/立方米的雄性和雌性大鼠中,慢性活动性炎症、巨噬细胞增生、肺泡蛋白沉积症和纤维化的发生率显著增加。在2年研究结束时,0.5毫克/立方米雄性和雌性大鼠支气管淋巴结中淋巴样增生的发生率增加。在研究结束时,0.5毫克/立方米雄性和雌性大鼠嗅上皮萎缩的发生率显著高于对照组。
在7个月和15个月的中期评估中,暴露的雄性和雌性大鼠肺部的镍负荷高于对照组,并且肺部镍负荷值随暴露浓度的增加而增加。
小鼠2年研究:将80只雄性和80只雌性小鼠通过吸入暴露于浓度为0、0.25、0.5或1毫克/立方米(相当于小鼠在第15个月时进行肺部和肾脏中的镍组织负荷评估。
生存、体重、临床发现和血液学:所有暴露组雄性和雌性的生存率与对照组相似。在研究的第二年,1毫克/立方米雄性和所有暴露组雌性的平均体重低于对照组。未发现被认为与化学暴露相关的临床发现或血液学差异。
在2年研究结束时,所有暴露组雄性和雌性小鼠的肺部均出现炎症病变。这些病变包括巨噬细胞增生、慢性活动性炎症、支气管化生(肺泡上皮增生)、肺泡蛋白沉积症和间质浸润细胞。在2年研究结束时,大多数1毫克/立方米雄性和雌性以及一些0.5毫克/立方米雌性的支气管淋巴结中出现巨噬细胞增生和/或淋巴样增生。在2年研究结束时,0.5和1毫克/立方米雄性以及所有暴露组雌性中观察到嗅上皮萎缩。
在7个月和15个月的中期评估中,对照组和暴露组测量的肺部镍负荷参数低于检测限。在15个月时,0.5和1毫克/立方米肺部负荷研究雌性的绝对肺重量显著大于对照组。
测试了六水合硫酸镍(500至800微克/毫升)在L5178Y小鼠淋巴瘤细胞中诱导三氟胸苷抗性的能力。在无S9的情况下观察到阳性反应。未使用S9进行该测试。
在这些2年吸入研究的条件下,没有证据表明暴露于0.12、0.25或0.5毫克/立方米(0.03、0.06或0.11毫克镍/立方米)的六水合硫酸镍对雄性或雌性F344/N大鼠具有致癌活性。没有证据表明暴露于0.25、0.5或1毫克/立方米(小鼠吸入六水合硫酸镍2年导致肺部慢性活动性炎症、巨噬细胞增生、肺泡蛋白沉积症和纤维化的发生率增加;支气管淋巴结的淋巴样增生;以及嗅上皮萎缩。小鼠吸入六水合硫酸镍2年导致肺部慢性活动性炎症、支气管化生(肺泡上皮增生)、巨噬细胞增生、间质浸润和肺泡蛋白沉积症的发生率增加;支气管淋巴结的淋巴样和巨噬细胞增生;以及嗅上皮萎缩。
蓝盐;六水合物,镍(2+)盐;硫酸镍单水合物;六水合镍(2+)硫酸盐;六水合镍(II)硫酸盐;六水合硫酸镍;六水合亚镍硫酸盐;六水合亚镍;单镍盐,硫酸